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ABSTRACT
Background: Bone lytic lesion in Multiple myeloma are the most commonly presented 
symptoms which require treatment with bisphosphonates (BPs). BPs are providing support-
ive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria 
for stopping their administration have to be different from those used for classic antineo-
plastic drugs, and they should not be stopped when metastatic bone disease is progress-
ing. Osteonecrosis of the jaw (ONJ) has been associated recently with the use of BPs. Aim: 
The aim of these study is to evaluate the incidence of ONJ in patients with MM treated with 
mixed biphosphonates. Patients and methods: We analyzed total 296 myeloma patients 
(150 male and 146 female). Mostly effected age group with 58,1% is age more than 60 
years up to 88 years, diagnosed in our institution in the period 2005-2015. We used intrave-
nous or oral forms of biphosphonates such as pamidronate, ibandronate, clodronate and 
zolendronic acid. The patients were evaluated for ONJ. Results: The incidence of ONJ in our 
group of patients treated with Bps was 4,6% from our group of 260 patients 87,8% received 
BPs therapy and patients which haven’t received BPs 12,2%. From this group, 95,4% (248) 
didn’t show ONJ, and 4,6% (12) showed ONJ. The period of this treatment with BPs is an 
important risk factor for development of ONJ, average duration of BPs therapy in patients 
which show adverse effects is 26.8±13.7 months, from the total number of 12 patients that 
developed ONJ adverse effects, we have 8 patients which received treatment with Zolen-
dronic acid and the remaining 4 patients which were treated with other BPs combinations 
without Zolendronic acid. Conclusions: All patients treated for MM must continue with the 
therapy with Zolendronic acid and Pamidronate, each patient must be individually treated 
according to his response of the treatment (dose, frequency and duration of therapy).
Key words: Multiple myeloma, osteonecrosis of jaw, biphosphonates.
1. INTRODUCTION
Myeloma multiplex (MM) is the 
second most frequent hematolog-
ical malignancy, for approximately 
10% of all hematological malignan-
cies. It is characterized by malignant 
plasma cell infiltration of the bone 
marrow and is associated with an in-
creased level of monoclonal protein 
in the blood and/or urine. The un-
controlled growth of myeloma cells 
has many consequences like: skeletal 
destructions, anemia, and renal and 
immune impairments. Bisphospho-
nates (BPs) are potent inhibitors of 
osteoclast-mediated bone resorp-
tion, and it is well accepted that tu-
mor cells in bone, especially breast 
cancer and myeloma cells, can stim-
ulate osteoclast formation and activ-
ity leading to the release of growth 
factors or cytokines, which will fur-
ther stimulate cancer cells’ growth 
and their secretion of osteolytic fac-
tors (1). BPs are providing support-
ive care, reducing the rate of skeletal 
morbidity but evidently not abolish-
ing it, the criteria for stopping their 
administration have to be different 
from those used for classic antineo-
plastic drugs, and they should not 
be stopped when metastatic bone 
disease is progressing. However, 
criteria to determine whether and 
for how long an individual patient 
benefits from their administration 
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are lacking (2-7). New biochemical markers of bone re-
sorption might help identify those patients continuing 
to benefit from therapy. Even better results have been 
achieved in patients with multiple myeloma, and the 
general consensus is that BPs should be started as soon 
as the diagnosis of lytic disease is made in myeloma pa-
tients (8). For multiple myeloma patients who have, on 
plain radiographs or imaging studies, lytic destruction 
of bone or spine compression fracture from osteopenia, 
intravenous pamidronate 90mg delivered over at least 2 
hours, or zolendronic acid 4mg delivered over at least 15 
minutes every 3 to 4 weeks is recommended (9). Unfor-
tunately long term use of biphosphonates shows adverse 
effects like osteonecrosis of the jaw ONJ, who is uncom-
mon but potentially serious complication of intravenous 
application of biphosphonates, because of it, The Update 
Committee agrees with a recommendations described 
in the revised US Food and Drug Administration label. 
Biphosphonate–related osteonecrosis of the jaw some-
times called BRONJ has shown increasing interest by 
dentists and oral maxillofacial surgeons, it is defined as 
an area of exposed bone in the maxillofacial region that 
does not heal within 8 weeks in a patient who is current-
ly receiving biphosphonate medication and has not had 
radiation to the head-neck region (1). The diagnosis is 
usually made clinically. More than 300 cases of ONJ as-
sociated with intravenous biphosphonate use in patients 
with cancer have been reported in the medical and den-
tal literature. From our Clinic we have the similar publi-
cation in 2010. The number of published cases with bi-
phosphonate-related osteonecrosis of the jaws (BRONJ) 
is steadily increased, but the definite prevalence is still 
unknown. The incidence rate is higher in patients with 
high dose intravenous administration of biphosphonates 
compared to the oral route of administration, but some-
times the condition occurs also in patients with low dose 
osteoporotic treatment (10). The estimates of BRONJ for 
i.v. application range from around 1 to 21% (1, 8, 11, 12) 
because they have various underlying diseases, also very 
important is drug potency like zolendronat which is the 
most potent bisphosphonate and patients received i.v. 
zolendronat for cancer indication (11, 12). For example, a 
web-based survey of ONJ in 2004 found that ONJ devel-
oped in 10% of patients receiving zoledronate compared 
to 4% of patients receiving pamidronate (8). As we men-
tioned one of the risk factor is the type of administration 
as well as individual local and systemic conditions, as-
ymptomatic form for a long time, do not relate their oral 
symptoms to the biphosphonate therapy. ONJ is associ-
ated with i.v. bisphosphonate a less with oral bisphos-
phonate (14). The cumulative dose of bisphosphonate is 
also considered to be an important factor in the develop-
ment of ONJ and it is determined by the dose, frequency 
of administration, duration of therapy and half-life of the 
drug (1, 8, 11, 12, 14).
A history of dental disease, including invasive dental 
procedures, dental trauma and periodontal disease, may 
also be an important risk factor for the development of 
ONJ in association with bisphosphonates (8, 11). The 
most representative study, however with a retrospective 
review of 830 patients, showed an ONJ incidence of 8,2%.
2. AIM
The aim of these study was to evaluate the incidence 
of ONJ in patients with MM treated with mixed biphos-
phonates, even with zolendronic acid in a period of 10 
years, in our institution, with is rapid increased because 
in our last study in 2010 we had a incidence of 1% from 
observed patients (14).
3. PATIENTS AND METHODS
We retrospectively analyzed total 296 myeloma pa-
tients (150 male and 146 female) with average age of 62 
years ±10,3 years. Mostly effected age group with 58,1% 
is age more than 60 years up to 88 years, diagnosed in 
our institution in the period 2005-2015. Bone disease 
affects more than 70% of patients with MM and is as-
sociated with pain, pathological fractures and hyper-
calcaemia. Bone disease is important morbidity factor 
in patients with MM, and because of that measures for 
reducing morbidity from skeletal involvement are im-
portant in optimizing and improving a patient’s quali-
ty of life. Monthly infusion of biphosphonates reduces 
skeletal events and modifies the natural history of bone 
disease in MM.
We used intravenous or oral forms of biphosphonates 
such as pamidronate, ibandronate, clodronate and zolen-
dronic acid. Mostly common we used oamidronate 90mg 
i.v. or ibandronate 6mg i.v. per month or zolendronic 
acid 4mg per month. Oral biphosphonates we used like 
standard dose of clodronate or ibandronate every day all 
month long. Details of the disease such as lasting of the 
type of MM treatment, biphosphonates therapy and last-
ing of the same was analyzed for all patients. The patients 
which developed adverse effects of biphosphonates 
treatment like osteonecrosis of the jaw (mostly mandi-
ble) and maxilla, were treated with surgical debridement 
and received broad spectrum of antibiotics before and 
after the surgery and afterwards the bisphosponate ther-
apy was stopped after the X-Ray signs of ONJ.
4. RESULTS
The incidence of ONJ in our group of patients treat-
ed with biphosphonates was 4,6% from our group of 
260 patients 87,8% received BPs therapy and patients 
which haven’t received BPs 12,2%. From this group of 
260 patients, 95,4% (248) didn’t show ONJ, and 4,6% (12) 
showed ONJ. According to Bamias et al., the incidence 
of ONJ in patients with MM treated with BPs was 11 





Received BPs 260 87.8
NO 248 95.4
YES 12 4.6
Not received BPs 36 12.2
Total 296 100.0 total 260 100.0
Table 1. Distribution of patients according to adverse 
effect from biphosphonate therapy
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was 1% (14). Th e incidence has grown because we started 
using zolendronic acid which is the most commonly re-
ferred biphosphonate is causing ONJ. Our results co-re-
late with the world experiences, in the literature. Th e 
period of this treatment with BPs is an important risk 
factor for development of ONJ.
Biphosphonate therapy was received by 260 (87,8%) 
patients, and 36 (12,2%) didn’t receive biphosphonate 
therapy (Table 1).
Adverse eff ect from biphosphonate therapy is not reg-
istered with 94,4 patients which received biphosphonate 
therapy, and adverse eff ects are registered (such as osteo-
necrosis of the jaw) with 4,6% of patients which received 
biphosphonate therapy (Table 1).
No Average Minimum Maximum St. Dev.
Total 260 20.9 1.0 100.0 19.41460
No ONJ 248 20.6 1.0 100.0 19.62398
ONJ 12 26.8 6.0 63.0 13.71877
Table 2. Average lasting of biphosphonate therapy with 
patients which have registered adverse eff ects
Average duration of biphosphonate therapy in patients 
is 20.9±19.4 months, minimum 1 month and maximum 
100 months (Table 2, Figure 2). Average duration of bi-
phosphonate therapy in patients which don’t show ad-
verse eff ects is 20.6±19.6 months, minimum 1 month, 
and maximum 100 months (Table 2 and Figure 2). Aver-
age duration of biphosphonate therapy in patients which 
show adverse eff ects is 26.8±13.7 months, minimum 6 
months and maximum 63 months (Table 2 and Figure 2). 
According to t-test the diff erence is statistically insignifi -
cant for p<0.05 (t=-1.07329, p=0.284145).
Single-type-biphosphonate therapy is used by 54,6% 
of patients and combination of biphopshonate therapy is 
used by 45,4% of patients (Table 3 and Figure 3).
From the total number of 12 patients that developed 
ONJ adverse eff ects, we have 8 patients which received 
treatment with Zolendronic acid and the remaining 4 pa-
tients which were treated with other BPs combinations 
without Zolendronic acid. Patients received i.v. zolen-
dronic and pamidronate and only one received per os. 
Th erefore the use of Zolendronic acid is a major risk fac-
tor in the incidence of ONJ.
5. DISCUSSION
Th e use of biphosphonates seems to be associated 
with the development of ONJ. Our results correspond 
with those from the literature: the fi rst one is time of ex-
posure, their cumulative eff ect, type of biphosphonate 
mostly zolendronic acid, form of application like paren-
teral versus oral form, and previous dental procedures, 
like tooth extraction. Also potential risk factors for ONJ 
other than BPs include corticosteroids, coagulopathy, 
alcohol abuse, tobacco use, infections and infl amma-
tion. But steel prevention is superior to treatment, the 
establishment of oral hygiene and pre-emptive surgical 
treatment prior to application of BPs therapy is recom-
mended. Conservative management with antibiotic ther-
apy, improved local oral hygiene measures, 0,12% chlor-
hexidine mouth rinses and 2% potassium iodine solution 
maybe will relief signifi cant symptoms. Most important 
is surgical debridement, which probably becomes the 
treatment of choice for the management of ONJ. Th e 
time of exposure to BPs was strongly associated with the 
development of ONJ, the duration of BPs treatment in 
the study of Pavkovic M. et al. was 24.7±17.7 months, 
with median time 24 months and range of 2-84 months, 
compared to the Bamias A. et al. study where the medi-
an time of exposure to BPs and occurrence of ONJ was 
39,3 months. Th is is explained because of the lesser use 
of zolendronic acid, compared to the other studies. In 
all patients that showed a higher percentage, a treatment 
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Biphosphonate type  No % 
MONO 142 54.6 
COMBINATION OF 2 OR MORE 118 45.4 
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Figure 3. Graphic showing of the usage of biphosphonate type 
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surgical treatment becomes unavoidable referral to a specialist oral and maxillofacialist surgeon is 
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we have an increased percentage compared to the 2010 
study. When surgical treatment becomes unavoidable 
referral to a specialist oral and maxillofacial surgeon is 
recommended, extraction and all types of surgery to the 
jaws should be avoided. According to Cheng et al. there 
is a novel approach of slow extraction using orthodon-
tic bands (15). One of the option is laser therapy at low 
intensity, segmental osteotomies and hyperbaric oxygen, 
but all these therapies are based on individual approach 
to the patient (16-19). Patients that take BPs can some-
times show ON of the jaws but most commonly it is as-
sociated with trauma, predominantly dental extraction. 
We can not predict who has a higher risk for BRONJ 
while using BPs. One of the persistent conclusions is the 
correlation between duration of therapy and occurrence 
of BRONJ. We have also used antibiotics while treating 
BRONJ but with small effects. Debridement’s from sur-
gery and wound closure worsens the symptoms and even 
excessive osseous surgery has resulted in enlargement of 
areas of necrotic bone. The conclusion is that the best 
way is to use conservative debridement. However, the 
choice between surgery and conservative therapy is a dif-
ficult issue and must be made on an individual basis (20). 
All those patients, treated with antibiotics and surgically 
treated, which developed ONJ had a small benefit from 
the same, the most important is the prophylaxis and the 
preventive measures: education of the patient about po-
tential adverse effects associated with the therapy, early 
detection and non-surgical of oral conditions, mainte-
nance of oral hygiene program.
6. CONCLUSION
The conclusion of this study comes to similar con-
clusions as other authors. All patients treated for MM 
must continue with the therapy with Zolendronic acid 
and Pamidronate, each patient must be individually 
treated according to his response of the treatment (dose, 
frequency and duration of therapy). The medications 
must be administrated in a monthly frequency the first 
year and every three months in the forthcoming years. 
Involvement of surgery should be avoided and put to a 
lesser level, only in cases where it is mandatory.
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